232 related articles for article (PubMed ID: 36647077)
1. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results.
Forsythe E; Haws RM; Argente J; Beales P; Martos-Moreno GÁ; Dollfus H; Chirila C; Gnanasakthy A; Buckley BC; Mallya UG; Clément K; Haqq AM
Orphanet J Rare Dis; 2023 Jan; 18(1):12. PubMed ID: 36647077
[TBL] [Abstract][Full Text] [Related]
2. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
[TBL] [Abstract][Full Text] [Related]
3. Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome.
Ervin C; Norcross L; Mallya UG; Fehnel S; Mittleman RS; Webster M; Haqq AM; Haws RM
Adv Ther; 2023 May; 40(5):2394-2411. PubMed ID: 36961653
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM; Chung WK; Dollfus H; Haws RM; Martos-Moreno GÁ; Poitou C; Yanovski JA; Mittleman RS; Yuan G; Forsythe E; Clément K; Argente J
Lancet Diabetes Endocrinol; 2022 Dec; 10(12):859-868. PubMed ID: 36356613
[TBL] [Abstract][Full Text] [Related]
5. Burden of hyperphagia and obesity in Bardet-Biedl syndrome: a multicountry survey.
Forsythe E; Mallya UG; Yang M; Huber C; Cala ML; Greatsinger A; Hagopian E; Pomeroy J; Haqq AM
Orphanet J Rare Dis; 2023 Jul; 18(1):182. PubMed ID: 37415189
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design.
Haws RM; Gordon G; Han JC; Yanovski JA; Yuan G; Stewart MW
Contemp Clin Trials Commun; 2021 Jun; 22():100780. PubMed ID: 34013094
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.
Lazareva J; Brady SM; Yanovski JA
Expert Opin Pharmacother; 2023 Apr; 24(6):667-674. PubMed ID: 37013719
[TBL] [Abstract][Full Text] [Related]
8. Caregiver burden in Bardet-Biedl syndrome: findings from the CARE-BBS study.
Forsythe E; Mallya UG; Yang M; Huber C; Cala ML; Greatsinger A; Hagopian E; Pomeroy J; Haqq AM
Orphanet J Rare Dis; 2023 Jul; 18(1):181. PubMed ID: 37415214
[TBL] [Abstract][Full Text] [Related]
9. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.
Haws R; Brady S; Davis E; Fletty K; Yuan G; Gordon G; Stewart M; Yanovski J
Diabetes Obes Metab; 2020 Nov; 22(11):2133-2140. PubMed ID: 32627316
[TBL] [Abstract][Full Text] [Related]
10. Hyperphagia among patients with Bardet-Biedl syndrome.
Sherafat-Kazemzadeh R; Ivey L; Kahn SR; Sapp JC; Hicks MD; Kim RC; Krause AJ; Shomaker LB; Biesecker LG; Han JC; Yanovski JA
Pediatr Obes; 2013 Oct; 8(5):e64-7. PubMed ID: 23776152
[TBL] [Abstract][Full Text] [Related]
11. Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management.
Shoemaker A
Diabetes Obes Metab; 2024 Apr; 26 Suppl 2():25-33. PubMed ID: 38383825
[TBL] [Abstract][Full Text] [Related]
12. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
Trapp CM; Censani M
Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):136-140. PubMed ID: 36722447
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
Kolotkin RL; Chen S; Klassen P; Gilder K; Greenway FL
Clin Obes; 2015 Oct; 5(5):237-44. PubMed ID: 26222044
[TBL] [Abstract][Full Text] [Related]
14. [Improved Care and Treatment Options for Patients with Hyperphagia-Associated Obesity in Bardet-Biedl Syndrome].
Cetiner M; Bergmann C; Bettendorf M; Faust J; Gäckler A; Gillissen B; Hansen M; Kerber M; Klaus G; König J; Kühlewein L; Oh J; Richter-Unruh A; von Schnurbein J; Wabitsch M; Weihrauch-Blüher S; Pape L
Klin Padiatr; 2024 Mar; ():. PubMed ID: 38458231
[TBL] [Abstract][Full Text] [Related]
15. The relationship between health-related quality of life and weight loss.
Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S
Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837
[TBL] [Abstract][Full Text] [Related]
16. Development of a brief measure to assess quality of life in obesity.
Kolotkin RL; Crosby RD; Kosloski KD; Williams GR
Obes Res; 2001 Feb; 9(2):102-11. PubMed ID: 11316344
[TBL] [Abstract][Full Text] [Related]
17. Bardet-Biedl syndrome: Weight patterns and genetics in a rare obesity syndrome.
Pomeroy J; Krentz AD; Richardson JG; Berg RL; VanWormer JJ; Haws RM
Pediatr Obes; 2021 Feb; 16(2):e12703. PubMed ID: 32700463
[TBL] [Abstract][Full Text] [Related]
18. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
Kolotkin RL; Gabriel Smolarz B; Meincke HH; Fujioka K
Clin Obes; 2018 Feb; 8(1):1-10. PubMed ID: 29045079
[TBL] [Abstract][Full Text] [Related]
19. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample.
Kolotkin RL; Crosby RD
Qual Life Res; 2002 Mar; 11(2):157-71. PubMed ID: 12018739
[TBL] [Abstract][Full Text] [Related]
20. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Kolotkin RL; Corey-Lisle PK; Crosby RD; Kan HJ; McQuade RD
Eur Psychiatry; 2008 Dec; 23(8):561-6. PubMed ID: 18374544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
